Pricing Log in Create free account

Can-Fite Biopharma Ltd (CANF) vs Cardio Diagnostics Holdings, Inc. (CDIO)

Can-Fite Biopharma Ltd and Cardio Diagnostics Holdings, Inc. are both Biotechnology companies. Can-Fite Biopharma Ltd and Cardio Diagnostics Holdings, Inc. are of similar size ($5.6M and $5.2M). Can-Fite Biopharma Ltd grew revenue faster over the last twelve months: −3.36% against −25.1%. Can-Fite Biopharma Ltd has the higher net margin (−1,148.6% vs −44,312.3%) and the higher return on invested capital (0.00% vs −219.4%). Across the 17 metrics below, Can-Fite Biopharma Ltd leads on 9 and Cardio Diagnostics Holdings, Inc. on 8.

Valuation

Metric CANF CDIO Biotechnology median
P/E n/m n/m 8.50
P/S 0.45 342.57 9.71
P/B 0.07 0.67 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.58 0.10 0.64
EV/Sales (8.64) (40.08) 9.21
Earnings yield (738.94%) (172.78%) (33.15%)
Free cash flow yield (5,538.69%) (116.45%) (25.50%)

Profitability

Metric CANF CDIO Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (44,230.82%) 0.00%
Net margin (1,148.62%) (44,312.33%) 0.00%
Free cash flow margin 0.00% (39,893.15%) 0.00%
Return on equity 0.00% (75.44%) (56.36%)
Return on assets 0.00% (70.62%) (48.04%)
Return on invested capital 0.00% (219.40%) 0.00%

Growth

Metric CANF CDIO Biotechnology median
Revenue growth (TTM) (3.36%) (25.13%) 6.02%
EPS growth (last fiscal year) 45.23% 60.15% 30.26%
Revenue growth, 5-year CAGR (11.90%) — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CANF CDIO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.60 17.15 4.72
Net debt to EBITDA 0.86 0.84 0.96

Dividend

Metric CANF CDIO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CANF CDIO Biotechnology median
Market cap 5.61m 5.21m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack